This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT04881760 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 338 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight |
| Interventions | LY3437943; Placebo |
| Start | May 20, 2021 |
| Primary completion | May 16, 2022 |
| Study completion | Nov 22, 2022 |
| Results posted | Yes, in the registry |
| Registry last updated | Sep 13, 2023 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Mean Percent Change From Baseline in Body Weight | Baseline, Week 24 |
13 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
